IntraLinks Survey Finds that 86 Percent of Biotech and Pharmaceutical Executives Expect to Conduct Deal Activity over the next 12 Months

New York, April 30, 2010 — IntraLinks, a leading provider of critical information exchange solutions, today announced the results of the latest IntraLinks Life Sciences Deal Activity Survey, which was conducted at the recent BioNetwork East 2010 Conference in Miami, Fla. The BioNetwork East Conference provided an interactive forum for key members of the pharmaceutical and biotech communities to network, discuss business challenges and exchange information. The event was attended by business development executives from leading global companies such as AstraZeneca, Pfizer, Novartis and GlaxoSmithKline.

The survey results indicate that 86 percent of respondents expect deal activity over the next 12 months, consistent with findings from the previous survey that IntraLinks conducted in October 2009 at the BioNetwork West Conference. Forty-seven percent of the respondents anticipate that deals will involve in-licensing or out-licensing an asset, with the remainder divided among alliances, purchases and financing. In line with the type of deals projected, 49 percent of respondents envisioned that more than half of their deals would involve large, confidential documents which are typically hyperlinked, such as Investigational New Drug Applications (INDs) or New Drug Applications (NDAs).

“Our survey findings clearly indicate that there will be continued deal activity in the life sciences industry during the next 12 months,” said Alison Shurell, VP, life sciences product marketing, IntraLinks. “Business development and licensing teams in the life sciences industry are under significant pressure to initiate and complete deals rapidly in order to meet corporate goals but continue to face a myriad of challenges that are associated with this resource-intensive and document-heavy process. IntraLinks’ SaaS-based, document sharing and collaboration platform securely accelerates the due diligence process during deal activity, alleviating administrative burden, reducing prep time and cutting direct costs. IntraLinks’ unique ability to maintain the “link integrity” of regulatory documents for review in a secure, online environment is also a key benefit for users, particularly as the survey findings indicate there will be a significant number of deals with large, linked documents.”

Pharmaceutical and biotech professionals that are working on business development and licensing opportunities use IntraLinks to raise capital, evaluate opportunities, expedite due diligence, manage alliances and capture institutional knowledge. The top 10 global pharmaceutical companies and top 10 biotechs in the world have all utilized IntraLinks’ platform. IntraLinks also provides a secure solution for document exchange during clinical trials, from study start-up, through study conduct, safety review and close out. Clinical Research Organizations (CROs), sponsors, Institutional Review Boards (IRBs) and investigative sites use IntraLinks to better manage, track and exchange regulatory documents, study participant information and Serious Adverse Event (SAE) reports.

The key statistics from the latest IntraLinks Life Sciences Deal Activity Survey include:

Number of deals anticipated over the next 12 months:

• 72% of respondents anticipate doing between one and 10 deals
• 14% of respondents anticipate doing more than 11 deals
• 14% of respondents don’t anticipate doing any deals

Percentage of deals expected to include large, linked documents in the due diligence material:

• 49% of respondents anticipate more than half of their deals will include large linked docs
• 38% of respondents anticipate up to 50% of deals will include large linked docs
• 13% of respondents did not answer the question

Type of deals anticipated over the next 12 months:

• 47% of respondents anticipate in-licensing or out-licensing an asset
• 21 % anticipate co-developing or co-promoting an alliance
• 21% anticipate the outright purchase of an asset or company
• 11% anticipate other deals, such as securing financing

The survey findings are based on feedback from 72 people, almost half the attendees at the BioNetwork East Conference.